Cutaneous T Cell Lymphoma Ctcl Pipeline Insight

DelveInsight’s, “Cutaneous T-Cell Lymphoma (CTCL) - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cutaneous T-Cell Lymphoma (CTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Cutaneous T-Cell Lymphoma (CTCL) Understanding

Cutaneous T-Cell Lymphoma (CTCL): Overview

Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin’s lymphomas that are characterized by a cutaneous infiltration of malignant monoclonal T lymphocytes. In Cutaneous T-Cell Lymphoma (CTCL), the T cells develop abnormalities that make them attack the skin. Cutaneous T-Cell Lymphoma (CTCL) can cause rash-like skin redness, slightly raised or scaly round patches on the skin, and, sometimes, skin tumors. The diagnosis of CTCLs is difficult at early stages because of the presence of multiple clinical presentations and lack of definitive diagnostic criteria. The diagnosis is based upon a thorough clinical evaluation, detection of certain symptoms and physical findings, a detailed patient history, and a variety of specialized tests. The risk of developing this rare cancer increases with age. Most people are diagnosed when they are in their 50s or older. Biopsies typically involve surgical removal and microscopic examination (i.e., histologic) of small samples of tissue cells gathered from CTCL skin lesions. The most common type and classic presentation of CTCL is known as mycosis fungoides and usually progresses slowly over many years. Treatment options may include: Skin creams and ointments, Light therapy (phototherapy), Radiation therapy, Medications, Exposing blood cells to light, and Bone marrow transplant.


"Cutaneous T-Cell Lymphoma (CTCL) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cutaneous T-Cell Lymphoma (CTCL) pipeline landscape is provided which includes the disease overview and Cutaneous T-Cell Lymphoma (CTCL) treatment guidelines. The assessment part of the report embraces, in depth Cutaneous T-Cell Lymphoma (CTCL) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cutaneous T-Cell Lymphoma (CTCL) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous T-Cell Lymphoma (CTCL) R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous T-Cell Lymphoma (CTCL).

Cutaneous T-Cell Lymphoma (CTCL) Emerging Drugs Chapters

This segment of the Cutaneous T-Cell Lymphoma (CTCL) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Cutaneous T-Cell Lymphoma (CTCL) Emerging Drugs


Naloxone Hydrochloride: Elorac

Naloxone lotion is an investigational opiate antagonist designed to relieve pruritus associated with CTCL. The drug is currently in Phase III clinical evaluation for the treatment of Cutaneous T-Cell Lymphoma (CTCL). Elorac received Orphan Drug Designation for naloxone hydrochloride lotion from both FDA and the European Medicines Agency. Elorac also has Fast Track designation from FDA for this novel investigational new drug.


Cobomarsen: Viridian Therapeutics

Cobomarsen is an inhibitor of microRNA-155. microRNA-155 is believed to play an important role in the proliferation and survival of malignant cancer cells in certain types of blood cancer. The drug is currently in Phase II clinical evaluation for the treatment of Cutaneous T-Cell Lymphoma (CTCL) (CTCL). On 23rd July 2020, miRagen Therapeutics (now Viridian Therapeutics) announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma.

Further product details are provided in the report……..

Cutaneous T-Cell Lymphoma (CTCL): Therapeutic Assessment

This segment of the report provides insights about the different Cutaneous T-Cell Lymphoma (CTCL) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Cutaneous T-Cell Lymphoma (CTCL)

There are approx. 25+ key companies which are developing the therapies for Cutaneous T-Cell Lymphoma (CTCL). The companies which have their Cutaneous T-Cell Lymphoma (CTCL) drug candidates in the most advanced stage, i.e. Phase III include, Elorac.

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Cutaneous T-Cell Lymphoma (CTCL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cutaneous T-Cell Lymphoma (CTCL): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cutaneous T-Cell Lymphoma (CTCL) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous T-Cell Lymphoma (CTCL) drugs.

Cutaneous T-Cell Lymphoma (CTCL) Report Insights

  • Cutaneous T-Cell Lymphoma (CTCL) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Cutaneous T-Cell Lymphoma (CTCL) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Cutaneous T-Cell Lymphoma (CTCL) drugs?
  • How many Cutaneous T-Cell Lymphoma (CTCL) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous T-Cell Lymphoma (CTCL)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cutaneous T-Cell Lymphoma (CTCL) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cutaneous T-Cell Lymphoma (CTCL) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Cutaneous T-Cell Lymphoma (CTCL): Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Cutaneous T-Cell Lymphoma (CTCL) – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Cutaneous T-Cell Lymphoma (CTCL) companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Cutaneous T-Cell Lymphoma (CTCL) Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Naloxone Hydrochloride: Elorac

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Cobomarsen: Viridian Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Sofusa anti-PD1: Sorrento Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

VDA-1102: VidacPharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Cutaneous T-Cell Lymphoma (CTCL) Key Companies

Cutaneous T-Cell Lymphoma (CTCL) Key Products

Cutaneous T-Cell Lymphoma (CTCL)- Unmet Needs

Cutaneous T-Cell Lymphoma (CTCL)- Market Drivers and Barriers

Cutaneous T-Cell Lymphoma (CTCL)- Future Perspectives and Conclusion

Cutaneous T-Cell Lymphoma (CTCL) Analyst Views

Cutaneous T-Cell Lymphoma (CTCL) Key Companies

Appendix

List of Table

Table 1: Total Products for Cutaneous T-Cell Lymphoma (CTCL)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Cutaneous T-Cell Lymphoma (CTCL)

Figure 2: Late Stage Products                              

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Soligenix

• Elorac

• 4SC AG

• Merck Sharp & Dohme Corp.

• Innate Pharma

• Viridian Therapeutics

• Sorrento Therapeutics

• Bio-Path Holdings, Inc.

• Legend Biotech USA Inc.

• Genzada Pharmaceuticals

• VidacPharma

• Medc Biopharma

  • Tags:
  • Cutaneous T-Cell Lymphoma (CTCL) Pi...
  • Cutaneous T-Cell Lymphoma (CTCL) c...
  • Cutaneous T-Cell Lymphoma (CTCL) c...
  • Cutaneous T-Cell Lymphoma (CTCL) d...
  • Cutaneous T-Cell Lymphoma (CTCL) t...
  • Cutaneous T-Cell Lymphoma (CTCL) t...
  • Cutaneous T-Cell Lymphoma (CTCL) p...
  • Cutaneous T-Cell Lymphoma (CTCL) p...

Forward to Friend

Need A Quote